Incyte Corporation (NASDAQ:INCY), According to the latest information the short interest in Incyte Corporation plummeted by 12.1% or 754,611 shares. The final shorts are 2.9% of the total floated shares. The positions dropped from 6,217,653 shares on May 31,2016 to 5,463,042 on June 15,2016. According to the per-day average trading of 974,053 shares, the days to cover are 6. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Incyte Corporation (NASDAQ:INCY): The stock opened at $76.84 on Friday but the bulls could not build on the opening and the stock topped out at $80.89 for the day. The stock traded down to $76.41 during the day, due to lack of any buying support eventually closed down at $76.98 with a loss of -5.73% for the day. The stock had closed at $81.66 on the previous day. The total traded volume was 2,384,331 shares.
The company shares have dropped -23.65% from its 1 Year high price. On Sep 16, 2015, the shares registered one year high at $133.62 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $79.16 and the 200 Day Moving Average price is recorded at $80.37.
Incyte Corporation (NASDAQ:INCY) has tumbled 0.17% during the past week and has dropped 8.93% in the last 4 week period. The company has outperformed the S&P 500 by 1.49% in the past week but underperformed the index by 6.18% in the last 4 weeks.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f